Meeder Asset Management Inc. increased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 26.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 148,668 shares of the company’s stock after buying an additional 31,476 shares during the quarter. Johnson & Johnson makes up about 2.0% of Meeder Asset Management Inc.’s portfolio, making the stock its 9th largest position. Meeder Asset Management Inc.’s holdings in Johnson & Johnson were worth $39,358,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. CKW Financial Group increased its stake in shares of Johnson & Johnson by 0.9% during the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock valued at $1,104,000 after buying an additional 37 shares during the period. Silver Coast Investments LLC lifted its stake in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV lifted its stake in Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after acquiring an additional 39 shares during the period. Triumph Capital Management lifted its stake in Johnson & Johnson by 1.6% in the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after acquiring an additional 39 shares during the period. Finally, Kwmg LLC boosted its holdings in Johnson & Johnson by 1.7% in the third quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after acquiring an additional 39 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on JNJ. Johnson Rice downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Citigroup raised their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. HSBC lifted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Guggenheim reiterated a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.92.
Insider Transactions at Johnson & Johnson
In other news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $272.75 on Thursday. Johnson & Johnson has a 12 month low of $199.38 and a 12 month high of $290.25. The firm has a market capitalization of $656.58 billion, a P/E ratio of 41.33, a P/E/G ratio of 2.75 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $267.42 and a two-hundred day simple moving average of $250.61.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.
Johnson & Johnson Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
